

1 Indicators of COVID-19 status in a cohort study of university staff and post-graduate research  
2 students, including results from home antibody testing.

3 Authors: Katrina A. S. Davis\*<sup>1,2</sup>, Ewan Carr<sup>3</sup>, Daniel Leightley<sup>1</sup>, Valentina Vitiello<sup>4</sup>, Gabriella Bergin-  
4 Cartwright<sup>1,2</sup>, Grace Lavelle<sup>1</sup>, Alice Wickersham<sup>1,2</sup>, Michael H. Malim<sup>5</sup>, Carolin Oetzmänn<sup>1</sup>, Catherine  
5 Polling<sup>1,2</sup>, Sharon A.M Stevelink<sup>1</sup>, Reza Razavi<sup>+4</sup>, Matthew Hotopf<sup>+1,2</sup>, On behalf of the KCL CHECK  
6 research team

7 \* corresponding author

8 + joint last authors

9

10 (1) King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.

11 (2) South London and Maudsley NHS Foundation Trust, London.

12 (3) King's College London School of Biomedical Engineering and Imaging Sciences, Faculty of Life  
13 Sciences and Medicine, London, UK

14 (4) King's College London School of Immunology & Microbial Sciences, Faculty of Life Sciences  
15 and Medicine, London, UK

16

17 /Abstract/

18 Background: Cohort studies of people with a history of COVID-19 infection and controls will be  
19 essential to understand the epidemiology of long-term effects. However, clinical diagnosis requires  
20 resources that are frequently restricted to the severely ill. Cohort studies may have to rely on  
21 surrogate indicators of COVID-19 illness. We describe the prevalence and overlap of five potential  
22 indicators: self-reported suspicion, self-reported core symptoms, symptom algorithm, self-reported  
23 routine test results, and home antibody testing.

24 Methods: An occupational cohort of staff and postgraduate students at a large London university  
25 who participated in surveys and antibody testing. Self-report items cover March to June 2020 and  
26 antibody test results from 'lateral flow' IgG/IgM antibody test cassettes sent to participants in June  
27 2020.

28 Results: Valid antibody test results were returned for 1882 participants. Of the COVID-19 indicators,  
29 the highest prevalence was core symptoms (770 participants positive, 41%), followed by participant  
30 suspicion of infection (n=509, 27%), a symptom algorithm (n=297, 16%), study antibody positive test  
31 (n=124, 6.6%) and self-report of a positive external test (n=39, 2.1%). Study antibody positive result  
32 was rare in people who had no suspicion they had experienced COVID-19 (n=4, 0.7%) or did not  
33 experience core symptoms (n=10, 1.6%). When study antibody test results were compared with  
34 earlier external antibody results in those who had reported them, the study antibody results agreed  
35 in 88% cases (kappa= 0.636), with a lower proportion testing positive on this occasion (proportion  
36 with antibodies detected 15% in study test vs 24% in external testing).

37 Discussion: Our results demonstrate that there is some agreement between different COVID  
38 indicators, but that they a more complete story when used together. Antibody testing may provide  
39 greater certainty and be one of the only ways to detect asymptomatic cases, but is likely to under-  
40 ascertain due to weak antibody responses to mild infection, which wane over time. Cohort studies  
41 will need to review how they deal with different and sometimes conflicting indicators of COVID-19  
42 illness in order to study the long-term outcomes of COVID-19 infection and related impacts.

43

44 /Thumbnail/

45 *What is already known on this subject?*

46 Research into the effects of COVID-19 in the community is needed to respond to the pandemic.  
47 Objective testing has not been widely available and accuracy may not be high when carried out in  
48 retrospect. Many cohort studies are considering how best to measure COVID-19 infection status.

49 *What this study adds?*

50 Antibody testing is feasible, but it is possible that sensitivity may be poor. Each indicator included  
51 added different aspects to the ascertainment of COVID-19 exposure. Using combinations of self-  
52 reported and objectively measured variables, it may be possible to tailor COVID-19 indicators to the  
53 situation.

54

55 Acknowledgements:

56 The research team would like to thank the participants of KCL-CHECK and the team that has provided  
57 logistic and advisory support, in particular: Jonathan Edgeworth, Liam Jones, Lisa Sanderson, Jana  
58 Kim, Laila Danesh, Charlotte Williamson, Laurence Blight, Rupa Bhundia, Lucy O'Neill, Candice  
59 Middleton. We also thank Mark Zuckerman for comments on an earlier draft of this paper. This  
60 paper represents independent research supported by the National Institute for Health Research  
61 (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's  
62 College London. The views expressed are those of the author(s) and not necessarily those of the  
63 NHS, the NIHR or the Department of Health and Social Care. MHM is a Wellcome Trust Investigator.

64

65 Data availability

66 Researchers may access pseudonymised data by application to the Principal Investigators (Professor  
67 Matthew Hotopf, Professor Reza Razavi and Dr Sharon Stevelink, email: [check@kcl.ac.uk](mailto:check@kcl.ac.uk)) subject to  
68 conditions set out in the protocol <https://www.medrxiv.org/content/10.1101/2020.06.16.20132456v2>.

69

70 Competing interests

71 None declared.

72

73 Funding

74 This study was funded by King's College London.

75

## 76 1. Introduction

77 The majority of those affected by COVID-19 are community cases not requiring hospitalisation,[1]  
78 whilst most research has focussed on hospital admissions. Non-hospitalised presentations are  
79 important, not just because they are numerous, but also because there have been widespread  
80 concerns about the medium and long-term outcomes,[2-4] particularly so-called “long COVID” – i.e.  
81 chronic symptoms attributed to the disease which persist after the acute infection.[5] Whilst there is  
82 no “gold-standard” for diagnosing COVID-19,[6] in hospital cohorts, combined clinical assessment,  
83 antigen testing by polymerase chain reaction (PCR) and lung imaging provide a strong basis for  
84 diagnosis. By contrast, in community settings, particularly at the start of the pandemic where antigen  
85 testing was not widespread, such information is not available, and since tests such as antigen/PCR  
86 are time sensitive, many participants will have missed the window when such diagnostics would  
87 have been helpful. Since there are no “gold standard” methods by which researchers can distinguish  
88 between cases and controls in most community studies, researchers have to rely on proxy indicator  
89 measures of COVID-19.

90

91 Potential indicators of past COVID-19 include self-report and objective measures. Self-report includes  
92 (a) whether the participant thinks they had been infected, (b) the report of specific symptoms, and  
93 (c) self-report of testing, which is dependent not only on participant recall but also on the availability  
94 of testing at the time when the participant was ill. Objective measures include detection of  
95 antibodies produced in response to SAR-CoV-2 (the virus that causes COVID-19), either using  
96 enzyme-linked immunoassay (ELISA) in the laboratory or “point of care” kits that can be used in  
97 clinics or at home.[7] While there is guidance on the clinical use of tests for COVID-19,[8, 9] there is  
98 little guidance for cohort studies for choosing and interpreting these self-report and measured  
99 indicators. To appraise these methods, we therefore explore five potential indicators in the context  
100 of a cohort study of staff and post-graduate research students in London, UK, that has been running  
101 since April 2020 and undertook antibody testing in June 2020.[10, 11] Our aim was to provide a  
102 descriptive analysis of the overlapping indicators of COVID-19 measured during the first four months  
103 of the pandemic.

104

## 105 2. Methods

### 106 2.1 Study

107 The King’s College London Coronavirus Health and Experiences of Colleagues at King’s (KCL-CHECK)  
108 study explores the short-, medium-, and long-term health and wellbeing outcomes of the COVID-19  
109 pandemic (both the illness and the societal response) on KCL staff and postgraduate research (PGR)  
110 students. A protocol detailing study design and procedures is available.[10] Briefly, eligible  
111 participants were current staff or postgraduate research (PGR) students residing in the UK (for  
112 antibody testing). All KCL staff and PGR students were invited to participate via email on April 16<sup>th</sup>  
113 2020, with reminder emails and advertisements on internal social media over the following two  
114 weeks. The baseline survey was open for two weeks (participants who had started but not yet  
115 completed were reminded and given a further week to complete). Most (90%) of the participants  
116 opted into follow-up consisting of short surveys every two weeks and longer surveys every two  
117 months. There were a small number of participants (1%) who opted out of two-weekly surveys but  
118 agreed to two-monthly surveys.

119

#### 120 2.1.1 Ethics and reporting

121 Ethical approval has been gained from King’s College London Psychiatry, Nursing and Midwifery  
122 Research Ethics Committee (HR-19/20-18247). Participants provided informed consent to take part.

123 Reporting conforms to The Strengthening the Reporting of Observational Studies in Epidemiology  
124 (STROBE) guidelines,[12] and a checklist can be found in supplementary materials.

125

## 126 2.2 Measures

127 Table 1 shows the schedule for follow-ups, with the first follow-up survey referred to as Period 1  
128 (P1). Many questions in the baseline survey and longer follow-up surveys asked about experiences in  
129 the last two months, while the questions in the two-weekly follow-ups refer to experiences in the  
130 last two weeks. The present study used COVID-19 indicators from surveys at P0 (baseline) to P5 to  
131 measure exposures before the testing in late June. Questions asked in both the short and long  
132 surveys participant reports in P4 ('In the last two months') overlap with the reports in P1-3 ('In the  
133 last two weeks').

134

### 135 2.2.1 Self-reported suspicion of COVID-19 illness.

136 At the baseline (P0) survey participants were asked "Do you think that you have had COVID-19  
137 (coronavirus) at any time?". At two-weekly follow-ups (P1, P2, P3, and P5) participants were asked  
138 "Do you think that you have had COVID-19 (coronavirus) in the last two weeks?" At the two-monthly  
139 follow-up (P4) participants were asked "Do you think that you have had COVID-19 (coronavirus) in  
140 the last two months?". At all periods, participants could answer 'Definitely', 'Probably', 'Unsure' or  
141 'No'. These responses were summarised as the highest degree of suspicion ever reported for each  
142 participant (across P0 to P5). For some analyses report of 'Definitely' and 'Probably' were combined  
143 over surveys P0-P5, and if present, indicated positive suspicion of COVID-19.

144

### 145 2.2.2 Self-report of COVID symptoms

146 We adapted the symptom list used by the ZOE coronavirus daily reporting app [13] to cover two-  
147 month periods (P0 and P4) or two-week periods (P1, P2, P3 and P5), with a screening question "In  
148 the last two months[weeks], how have you felt physically?" and if they reported they had not been  
149 feeling well, they were taken to the checklist. If they reported shortness of breath or fatigue, they  
150 were asked about severity. We scored symptoms according to two definitions for comparison,  
151 representing examples of wider and more narrow definitions: (a) the presence of core symptoms of  
152 one or more of fever, cough and loss of smell/taste at any time; (b) scoring positively on a symptom  
153 algorithm described by the ZOE team using symptoms of loss of smell/taste loss, persistent cough,  
154 severe fatigue and skipped meals, participant age and gender [13]. Symptoms were summarised over  
155 all available survey periods as a binary indicator of whether participants had (i) ever vs. never scored  
156 positively on the ZOE algorithm, (ii) ever vs. never reported a core symptom, (iii) ever vs never  
157 reported feeling not right physically ('any symptom'). If participants missed a survey period they  
158 were considered to have not reported symptoms at that period.

159

### 160 2.2.3 Self-report of COVID-19 testing

161 We had no access to routine data or data collected for other studies on COVID-19 testing, so we  
162 asked "Have you had a test for COVID-19 (coronavirus)?" and "What was the result?" at baseline,  
163 and the same for the preceding two weeks at P1, P2, P3, and P5, and two months at P4. After the  
164 KCL-CHECK antibody tests were issued, we added the instructions to answer excluding the antibody  
165 kit we had sent them. At P8, we also asked participants to report separately about the type of test,  
166 asking about ever receiving tests involving a swab of the throat and/or nose to look for infection and,  
167 separately, about ever receiving blood and blood spot tests to look for evidence of past infection.  
168 These were used to split reported tests in P0 to P5 into "antigen/PCR tests" and "external antibody

169 tests". External testing was summarised over P0 to P5 as having 'ever' vs 'never' reported  
170 antigen/PCR or external antibody tests.

171

#### 172 2.2.4 Home antibody tests

173 A Rapid Immunoassay Test Cassette was used to measure evidence of antibodies to the 'spike'  
174 protein of SARS-CoV-2. The SureScreen Diagnostics COVID-19 IgG/IgM Rapid Test Cassette  
175 performance against antigen/PCR positive cases was shown to be good, for instance in laboratory  
176 conditions using samples from 110 hospitalised COVID-19 patients and 50 negative historical samples  
177 it had 89% sensitivity and 100% specificity, having >90% agreement with the ELISA result.[14]. An  
178 internal pilot demonstrated that the test cassette could be used by participants without specific  
179 training, following which we developed the procedure described in an earlier paper.[11] Briefly, the  
180 test cassette was sent by post to the participants' nominated address in late June, along with a  
181 lancet for providing a blood spot, the buffer solution and detailed illustrated instructions (available  
182 from the authors). Participants were asked to add blood then buffer to the cassette and wait ten  
183 minutes for results to appear. A printed rectangle labelled with the participant study ID number was  
184 provided within which the test cassette could be photographed, which they uploaded to a secure  
185 server. The team then interpreted the photographs. Participants were asked to contact the team if  
186 they had difficulties, who answered within two working days, and could arrange for a replacement  
187 kit to be sent if necessary (replacement kits were sent in early July).[11]

188

#### 189 2.2.5 Participant Characteristics

190 All characteristics were taken from the baseline survey (P0). Ethnicity was asked using recommended  
191 wording from the Office of National Statistics with 18 groups [15], and is reported grouped into five  
192 categories due to small cell sizes. Role within the university was grouped according to self-report  
193 main role and grouped based on likely seniority and exposure categories: academic, specialist and  
194 management; research, clerical and technical; teaching, facilities and clinical; and PGR student.  
195 Participants were also asked to indicate if they were in any of the government-defined roles that  
196 made them a "key worker".

197

#### 198 2.3 Analysis

199 Datasets from each period and antibody testing were merged using a 'longitudinal ID' that was  
200 allocated at baseline using R 4.0.0 and associated packages [16-19]. First, we summarised  
201 participation and missing data. Second, we explored the overlap of indicators through descriptive  
202 analysis and charts. 95% confidence intervals around proportions were calculated using Wilson's  
203 method. We refer to sensitivity and specificity of the self-report indicators for predicting those  
204 participants who were positive on the KCL-CHECK antibody test, as this was the objective measure  
205 available in this study. We do not necessarily regard this as sensitivity or specificity for past COVID-19  
206 illness or SARS-CoV-2 infection since we do not have a "gold-standard" diagnosis for comparison.

207

### 208 3. Results

#### 209 3.1 Cohort and Missing data

210 The baseline study included 2807 staff and PGR students, representing response a rate of 23%  
211 (Figure 1). Supplementary materials table ST1 and ST2 compare data about the composition of KCL  
212 staff and PGRs to the final cohort, and characteristics of staff and PGR students combined at each  
213 point in the survey is shown in Table 2. 1882 staff and PGR students who completed the baseline  
214 survey, consented to follow-up, and completed the antibody testing by 13th July with a valid result:

215 they were 88% white, 71% female, 17% PGR students and 13% keyworkers, with a median age of 37  
216 years.

217

218 After the baseline survey, there were five opportunities to complete follow up surveys before  
219 antibody test completion (see Table 1). 98% completed at least one survey, and 68% completed all  
220 five. Analyses were performed on the full cohort of 1882 participants and a secondary analysis  
221 limited to 1687 participants (90%) who had completed the P4 survey which, because it asked about  
222 the previous two months, provides a continuous record of COVID indicators covering time since  
223 baseline until around two weeks before the antibody tests were sent to participants. Prevalence and  
224 overlap of COVID indicators were identical in these analyses, so the larger cohort is reported.

225

### 226 3.2 COVID indicators

227 Table 3 shows the prevalence of COVID indicators in our sample. Of 1882 with valid antibody testing  
228 results, 124 tested positive (6.6% 95% confidence interval 5.6-7.8). This compares with 814 (41%,  
229 95%CI 39-43) who had experienced at least one core symptom, 527 (27%, 95%CI 25-29) who  
230 suspected they had experienced COVID-19 and 312 (16%, 95%CI 14-18) who were positive in the  
231 symptom algorithm. Around nine out of ten of these participants reported these indicators at  
232 baseline (90% with core symptoms, 91% suspected, 88% symptom algorithm). Only 323 people  
233 reported receiving a COVID-19 test (17%, 95%CI 16-19), not including the test from this study, with  
234 235 receiving a probable antigen/PCR test, and 138 receiving a probable external antibody test,  
235 including 50 reporting both. Ten reported a positive antigen/PCR test and 33 a positive external  
236 antibody test, meaning 2.1% (95%CI 1.5-2.8) of participants (12% of those tested) reported a positive  
237 external test.

238

239 Table 3 also shows the pattern of agreement between pairs of indicators. Universally, endorsing one  
240 indicator increased the likelihood participants met criteria for other indicators. Of people who  
241 endorsed at least one core symptom of COVID-19, 56% thought they had had COVID-19, but fewer  
242 met the symptom algorithm (39%) and fewer still were positive for antibodies (14%) or a positive  
243 external test (4%). When positive external test results were reported, all other criteria were met at  
244 least half the time. Of those who had tested positive on the KCL-CHECK antibody tests, 85% had  
245 experienced COVID-19 symptoms, 81% thought they had had COVID-19 and 67% met the symptom  
246 algorithm. In the KCL-CHECK antibody positive group, 19% reported a positive external test result: a  
247 further 9% reported having had external tests but not a positive test.

248

249 Taking into account agreement in both positive and negative outcomes, supplementary table ST3  
250 shows overall agreement ranged between 60%-94%, with the most likely to be concordant being  
251 KCL-CHECK antibody test and external test, followed by KCL-CHECK antibody test and symptoms  
252 algorithm; least likely to be concordant were core symptoms and external test. Considering the  
253 subset of 138 people who reported results of external antibody tests (Supplementary Table ST4),  
254 shows that 24% were positive on external tests, while 15% were positive on KCL-CHECK test. Overall  
255 agreement was 88% (Cohen's kappa=0.636).

256

257 Figure 2A and supplementary table ST5 show that if a participant thought they had not experienced  
258 COVID-19 they were very unlikely to get a positive antibody test result, with only 4 (0.7%) testing  
259 positive. The proportion testing positive steeply increased as suspicion increased, such that those  
260 who were definite were nearly 60 times more likely to test positive (39% positive), with probable or  
261 definite suspicion of COVID-19 infection having 81% sensitivity (101/124) and 77% specificity

262 (1350/1758) for KCL-CHECK positive antibody test. Figure 2B and supplementary table ST6 shows  
263 that the majority of people who tested positive on the KCL-CHECK antibody test were positive on the  
264 symptom algorithm in at least one survey. The algorithm had a 67% sensitivity (83/124) and 88%  
265 specificity (1544/1758) against the KCL-CHECK antibody test. Core symptoms (including all who were  
266 algorithm positive) had 85% sensitivity (106/124) and 62% specificity (1094/1758) against the KCL-  
267 CHECK antibody test. Comparing those who were positive on the symptom algorithm with those who  
268 had only core symptoms, algorithm positive participants were around six times as likely to test  
269 positively (28%:5%). Among participants not reporting any core symptoms, the proportion positive  
270 on KCL-CHECK test was no different between those who reported having potentially atypical  
271 symptoms and those who reported no symptoms at all (1.7% non-core/atypical symptoms:1.6% no  
272 symptoms).

273

274 Participant suspicion and self-reported symptoms were highly related. Table ST8 shows the  
275 proportion testing positive on KCL-CHECK antibody test for the intersections of suspicion and  
276 symptom with at least ten people. For each level of symptoms (algorithm, core, non-core, none)  
277 increasing suspicion increased the proportion having tested positive on the KCL-CHECK antibody test,  
278 such that suspicion seems to add information beyond symptom report. Those with the highest  
279 proportion of positive antibody results are those with algorithm positive and definite suspicion, at  
280 just 49% antibody positive.

281

#### 282 4. Discussion

283 Ascertaining who has and who has not had COVID-19 is not an easy undertaking, given symptoms  
284 that are variable and common, and availability of testing has been poor.[1] However cohort studies  
285 in the community must tackle this to answer some of the uncertainties and guide responses to this  
286 evolving pandemic.[4, 5] There are no “gold-standard” diagnostic criteria,[6] and for people with  
287 symptoms in the community who have not had the time-sensitive tests, there is now no opportunity  
288 to get diagnostic certainty, and therefore no “ground truth” of who has and who has not had COVID-  
289 19. For example, in the KCL-CHECK study, the vast majority (91%) of the people who thought they  
290 had experienced COVID-19 by June reported it in the baseline survey in April 2020, too late for any  
291 real-time ascertainment. Retrospective ascertainment using self-report and home testing kits have  
292 been used by KCL-CHECK to reduce some of the uncertainty, but none of these methods can recover  
293 the “ground truth”. This paper reports the results of each measure against the other to look at the  
294 merits of each approach and what can be learned for future studies.

295

296 The KCL-CHECK cohort was made up of staff and PGR students at the university. COVID indicators  
297 suggest a prevalence ranging from 2%-41% by June 2020. The 2% refers to positive external tests –  
298 but given that antigen testing was unavailable at the peak of infections, and performance depends  
299 on timing and swab technique, this will under-estimate COVID-19.[20] The 41% refers to reporting  
300 one or more core COVID-19 symptoms of fever, persistent cough and loss of smell/taste, the first  
301 two of which overlap with many other illnesses, so this will over-estimate symptomatic COVID-19.  
302 Report of little or no suspicion of COVID-19 was very predictive of antibody testing being negative,  
303 but false-positive report may be frequent due to the very high profile of the illness. However, we  
304 found that for each level of symptoms, higher self-reported suspicion adds to the likelihood of  
305 testing positive. Presumably participants are able to factor in both the symptom unusualness for  
306 them and external factors such as contact with someone with a history of COVID-19 illness.

307

308 The ZOE algorithm improves on using core symptoms to identify cases by including markers severity.  
309 In developing the algorithm we used they found that a single positive outcome on the algorithm had  
310 a sensitivity of 65% and specificity of 78% for antigen test outcome.[13]. In a separate cohort  
311 (TwinsUK), ever being algorithm positive during daily use of the app in March and April had a  
312 sensitivity of 37% and specificity of 95% for laboratory antibody testing.[21] In our study, algorithm  
313 positivity in any of up to six surveys had a sensitivity of 67% and specificity of 88% for home antibody  
314 test outcome. The higher sensitivity of the algorithm in our study reflects the fact that we found few  
315 asymptomatic people to be positive for antibodies (9% no symptoms, 15% no core symptoms),  
316 whereas they have been a substantial minority in many other studies, including TwinsUK (19% no  
317 symptoms, 27% no core symptoms), another UK study REACT2 (32% no symptoms, 39% no core  
318 symptoms)[22] and a study from Spain (22% no symptoms, 36% no core symptoms)[23]. Thus, while  
319 the algorithm may be good at identifying those with a classical COVID-19 illness, recalled symptoms  
320 alone will fail to identify all of those who have had the infection, for which testing may improve  
321 identification.

322

323 Antibody testing in KCL-CHECK used an IgG/IgM test kit based on a “lateral flow”, and could be sent  
324 to participants, was simple to use and had been shown under ideal settings to have high sensitivity  
325 (89% for serum from 110 hospital patients).[14] Antibody tests can be fallible though, giving false  
326 positives through cross-reactivity with antibodies unrelated to SARS-CoV-2 (possibly seasonal  
327 coronaviruses).[9] Our device reacted to none of the 50 control sera in Pickering et al., but most  
328 lateral flow devices tested on more controls give false positive results in approximately 2 per 1,000  
329 samples,[9, 24] which could be problematic in large studies with low prevalence. For the present  
330 study sensitivity is a concern, since it is known that small numbers of people do not produce anti-  
331 spike antibodies,[24, 25] they are detected more inconsistently in mild (i.e. non-hospitalised) COVID-  
332 19,[14, 26] and the concentration has been shown to decrease over time.[27, 28]. Testing in KCL-  
333 CHECK occurred at least three months after most people reported symptoms: few studies have yet  
334 tracked antibody levels over this length of time, but in some cases antibodies may cease to be  
335 detectable, especially on the qualitative lateral flow devices.[29, 30] In the subset of KCL-CHECK  
336 participants who had reported previous antibody testing 15% were positive on the KCL-CHECK  
337 antibody test, compared with 24% in their prior reported test, which could show time-dependent  
338 loss of reactivity, although there were likely to be differences in test specifications too.

339

340 Further rounds of testing may help elucidate the role of timing for antibody detection using lateral  
341 flow devices. There may be the possibility of augmenting antibody testing with testing for T cell  
342 response to SARS-CoV-2 to better track long-term immunity in the future.[31] For the present, it  
343 makes sense for studies to collect results from external testing from participants, which are likely to  
344 be accurate but under-estimate the proportion infected. Collecting enough symptom reports to  
345 calculate the ZOE algorithm will assist in finding those who have had a COVID-19-like illness, but both  
346 sensitivity and specificity may be added by also taking into account participant’s own appraisal of  
347 whether they have had COVID-19. Testing with a high specificity antibody test will identify past cases  
348 that were asymptomatic or atypically symptomatic and add more certainty where a positive test  
349 accords with COVID-19 symptoms. However, timing may lead to poor sensitivity when testing is done  
350 in isolation.

351

#### 352 4.1 Strengths and weaknesses

353 The strengths of this study include the survey repeating every fortnight, which we hope struck a  
354 balance between minimising recall bias for symptoms and participant burden. We incorporated a  
355 symptom checklist that has been evaluated elsewhere, alongside self-report suspicion of infection



356 and external testing, but also gave participants the opportunity to participate in antibody testing.  
357 The antibody test kit was chosen as being highly specific for SARS-CoV-2, and therefore suited to  
358 minimise false positives in population screening. While our conclusions could have been  
359 strengthened by the presence of a hospital standard diagnosis against which to compare other  
360 outcomes, the paper aimed to show what results can be gathered in the community and so  
361 compares these against each other.

362

363 Offering our participants home testing very likely improved uptake of the test at a time when people  
364 may have been put off attending a hospital due to infection concerns. The lateral flow cassette is  
365 designed for use by a trained person, but from our pilot and the high proportion of people returning  
366 valid results, we believe that with the procedures we had in place (such as illustrated instructions  
367 and a responsive email enquiry address) it was possible for participants to perform the test.[11]  
368 Nevertheless, there is the potential that participant errors and inconsistencies may have increased  
369 the number of invalid test results and potentially reduced sensitivity.

370

371 Our cohort was unusual for a population study because it was only including staff and PGR students  
372 from a single university; we found that women and people of white ethnicity were more likely to  
373 volunteer, as well as those in management and research roles, leading to a lack numbers and  
374 representativeness in some of the non-white ethnicities and lower socio-economic groups. We  
375 included all who had completed the baseline survey and antibody testing, regardless of missing  
376 intermediate surveys. Our sensitivity analysis showed this made little difference, which it intuitively  
377 would not given COVID-19 infections peaked at the end of March and estimated rates of infection  
378 were below 5 per 100,000 throughout May and June [32, 33] so we would expect relatively few  
379 positives to occur at timepoints in May and June compared to the baseline.

380

#### 381 4.2 Conclusions and implications

382 This paper shows a variety of potential COVID-19 indicators that may be available for community  
383 studies, their prevalence and overlap in a single cohort. All of the indicators are related and different  
384 combinations of self-reported and objective tests need to be considered in order to overcome the  
385 facts in this pandemic, such as time-course of detectable antigen and antibody, poor access to  
386 routine testing, symptoms that overlap with many other illnesses, and the high profile of the illness.  
387 Where false positives can be tolerated, it seems reasonable to take participant suspicion, whereas  
388 adding the symptom algorithm may increase specificity and an antibody test may add asymptomatic  
389 cases. With our present knowledge of COVID-19, it will be a case of maximising the algorithm for  
390 COVID-19 ascertainment, rather than one measure giving real certainty.

391

#### 392 Acknowledgements:

393 The research team would like to thank the participants of KCL-CHECK and the team that has provided  
394 logistic and advisory support, in particular: Jonathan Edgeworth, Liam Jones, Lisa Sanderson, Jana  
395 Kim, Laila Danesh, Charlotte Williamson, Laurence Blight, Rupa Bhundia, Lucy O'Neill, Candice  
396 Middleton. We also thank Mark Zuckerman for comments on an earlier draft of this paper. This  
397 paper represents independent research supported by the National Institute for Health Research  
398 (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's  
399 College London. The views expressed are those of the author(s) and not necessarily those of the  
400 NHS, the NIHR or the Department of Health and Social Care. MHM is a Wellcome Trust Investigator.

401

402 Competing interests

403 None declared.

404

405 Funding

406 This study was funded by King's College London.

407

Paper Tables

Table 1 Periods of data collection for KCL CHECK to week 18 (April – Aug 2020).

Table 2 Cohort characteristics at different points in the study, with the "valid antibody result" cohort being used in this paper

Table 3 The prevalence and overlap of positive COVID-19 indicators in KCL CHECK in order of prevalence in the main cohort (n=1882) with shading reflecting the strength of concordance.

Table 4 Proportion testing positive in intersecting groups of participant suspicion and self-reported symptoms (where at least 10 participants in the group). Depth of shading indicates proportion positive.

*Table 1 Periods of data collection for KCL CHECK to week 18 (April – Aug 2020).*

	<i>Timepoint</i>								
<i>Data collection period</i>	<i>P0 (Baseline)</i>	<i>P1</i>	<i>P2</i>	<i>P3</i>	<i>P4</i>	<i>P5</i>	<i>P6</i>	<i>P7</i>	<i>P8</i>
<i>Week of study</i>	<i>1-3</i>	<i>3-4</i>	<i>5-6</i>	<i>7-8</i>	<i>9-10</i>	<i>11-12</i>	<i>13-14</i>	<i>15-16</i>	<i>17-18</i>
<i>Month</i>	<i>April</i>	<i>May</i>		<i>June</i>			<i>July</i>		<i>Aug</i>
<b>Long survey</b> • “In the last two months”	<b>x</b>				<b>x</b>				<b>x</b>
<b>Short survey</b> • “In the last two weeks”		<b>x</b>	<b>x</b>	<b>x</b>		<b>x</b>	<b>x</b>	<b>x</b>	
<i>Antibody test</i>						<b>x</b>			

Table 2 Cohort characteristics at different points in the study, with the "valid antibody result" cohort being used in this paper

Cohort name (see figure 1)		Baseline	Longitudinal	Antibody result	Valid antibody result
Gender	Female	1948 (69%)	1769 (70%)	1418 (71%)	1339 (71%)
	Male	842 (30%)	760 (30%)	574 (29%)	533 (28%)
	Other	17 (1%)	15 (1%)	9 (1%)	9 (1%)
Role	Academic, specialist and management.	1075 (38%)	1060 (42%)	866 (43%)	810 (43%)
	Research, clerical and technical	809 (29%)	797 (31%)	661 (33%)	622 (33%)
	Teaching, facilities and clinical	204 (7%)	199 (8%)	142 (7%)	134 (7%)
	PGRs	536 (19%)	452 (18%)	334 (17%)	315 (17%)
	missing	183 (7%)	36 (1%)	1 (0%)	1 (0%)
Age-group (years)	18-24	136 (5%)	125 (5%)	93 (5%)	90 (5%)
	25-34	1084 (39%)	948 (37%)	732 (37%)	695 (37%)
	35-44	762 (27%)	698 (27%)	566 (28%)	535 (28%)
	45-54	440 (16%)	409 (16%)	316 (16%)	287 (15%)
	55-64	307 (11%)	288 (11%)	239 (12%)	220 (12%)
	65+	78 (3%)	76 (3%)	58 (3%)	55 (3%)
Ethnicity group	White	2152 (77%)	695 (27%)	535 (27%)	287 (15%)
	Mixed	102 (4%)	46 (1.8%)	34 (1.7%)	29 (1.5%)
	Asian	204 (7%)	191 (7.5%)	133 (6.6%)	125 (6.6%)
	Black	39 (1%)	37 (1.5%)	21 (1%)	20 (1.1%)
	Other	70 (2%)	69 (2.7%)	49 (2.4%)	44 (2.3%)
	missing	240 (9%)	23 (1%)	4 (0%)	4 (0%)
Keyworker status	keyworker	358 (13%)	357 (14%)	257 (13%)	242 (13%)
	non-keyworker	2449 (87%)	2187 (86%)	1747 (87%)	1640 (87%)
Total		2807	2544	2004	1882

PGRs: post-graduate research students

Table 3 The prevalence and overlap of positive COVID-19 indicators in KCL CHECK in order of prevalence in the main cohort (n=1882) with shading reflecting the strength of concordance.

	One or more core COVID-19 symptoms reported	Participant thinks they have had COVID-19	Symptom algorithm positive	KCL CHECK antibody test positive	Reports positive test result from elsewhere
Overall prevalence	770/1882, 41%	509/1882, 27%	297/1882, 16%	124/1882, 7%	39/1882, 2%
Number and proportion of column who also have:					
One or more core COVID symptoms reported		429 / 509 , 84%	297 / 297 , 100%	106 / 124 , 85%	31 / 39 , 79%
Participant thinks they have had COVID	429 / 770 , 56%		214 / 297 , 72%	101 / 124 , 81%	33 / 39 , 85%
Symptom algorithm positive	297 / 770 , 39%	214 / 509 , 42%		83 / 124 , 67%	25 / 39 , 64%
KCL -CHECK antibody test positive	106 / 770 , 14%	101 / 509 , 20%	83 / 297 , 28%		24 / 39 , 62%
Reports positive test result from elsewhere	31 / 770 , 4%	33 / 509 , 6%	25 / 297 , 8%	24 / 124 , 19%	

Table 4 Proportion testing positive in intersecting groups of participant suspicion and self-reported symptoms (where at least 10 participants in the group). Depth of shading indicates proportion positive.

		n antibody positive / N participants in intersect				
		% positive in intersect				
		Highest suspicion				
		no suspicion	unsure	probable	definite	overall
Most specific symptoms reported	symptom algorithm	N=7	10 / 76, 13%	40 / 146, 27%	33 / 68, 49%	<b>83 / 297, 28%</b>
	core symptoms	0 / 19, 0%	2 / 239, 1%	15 / 180, 8%	6 / 35, 17%	<b>23 / 473, 5%</b>
	non-core symptoms	0 / 154, 0%	4 / 263, 2%	3 / 51, 6%	N=2	<b>8 / 470, 2%</b>
	no symptoms	4 / 417, 1%	3 / 198, 2%	1 / 24, 4%	N=3	<b>10 / 642, 2%</b>
	overall	<b>4 / 597, 1%</b>	<b>19 / 776, 2%</b>	<b>59 / 401, 15%</b>	<b>42 / 108, 39%</b>	<b>124 / 1882, 7%</b>

Paper Figures

Figure 1 Study flowchart

Figure 2(A-B) KCL-CHECK antibody test result in June showing distribution of A. participant suspicion that they had experienced COVID-19 and B. highest level of symptoms reported, both between March and June. Participant numbers as labels




Figure 1 Study flowchart




Figure 2(A-B) KCL-CHECK antibody test result in June showing distribution of A. participant suspicion that they had experienced COVID-19 and B. highest level of symptoms reported, both between March and June. Participant numbers as labels

- 1 Anderson RM, Hollingsworth TD, Baggaley RF, *et al.* COVID-19 spread in the UK: the end of the beginning? *Lancet (London, England)* 2020.
- 2 Holmes EA, O'Connor RC, Perry VH, *et al.* Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *The Lancet Psychiatry* 2020.
- 3 Gupta A, Madhavan MV, Sehgal K, *et al.* Extrapulmonary manifestations of COVID-19. *Nature medicine* 2020;**26**:1017-32.
- 4 Josephson SA, Kamel H. Neurology and COVID-19. *JAMA* 2020;**324**:1139-40.
- 5 Rubin R. As Their Numbers Grow, COVID-19 "Long Haulers" Stump Experts. *JAMA* 2020.
- 6 Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. *BMJ* 2020;**369**:m1808.
- 7 Alter G, Seder R. The Power of Antibody-Based Surveillance. *Mass Medical Soc* 2020.
- 8 Deeks JJ, Dinnes J, Takwoingi Y, *et al.* Antibody tests for identification of current and past infection with SARS-CoV-2. *Cochrane Database of Systematic Reviews* 2020.
- 9 Hanson KE, Caliendo AM, Arias CA, *et al.* Infectious Diseases Society of America guidelines on the diagnosis of COVID-19. *Clinical Infectious Diseases* 2020.
- 10 Davis KA, Stevelink SA, Al-Chalabi A, *et al.* The King's College London Coronavirus Health and Experiences of Colleagues at King's Study (KCL CHECK) protocol paper: a platform for study of the effects of coronavirus pandemic on staff and postgraduate students. *medRxiv* 2020.
- 11 Leightley D, Vitiello V, Bergin-Cartwright G, *et al.* The King's College London Coronavirus Health and Experiences of Colleagues at King's Study: SARS-CoV-2 antibody response in an occupational sample. *medRxiv* 2020.
- 12 Von EE, Altman D, Egger M, *et al.* The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bmj* 2007;**335**:806-8.
- 13 Menni C, Valdes AM, Freidin MB, *et al.* Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nature Medicine* 2020.
- 14 Pickering S, Betancor G, Pedro Galao R, *et al.* Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. *medRxiv* 2020:2020.06.02.20120345.
- 15 Office for National Statistics (ONS). Ethnic group, national identity and religion: A guide for the collection and classification of ethnic group, national identity and religion data in the UK. *Classifications and harmonisation*. GOV.UK 2016.
- 16 Dowle M, Srinivasan A. data.table: Extension of `data.frame`. R package version 1.12.8. 2019.
- 17 R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2020.
- 18 Wickham H, Bryan J. readxl: Read Excel Files. R package version 1.3.1. 2019.
- 19 Wickham H, François R, Henry L, *et al.* dplyr: A Grammar of Data Manipulation. R package version 1.0.0. 2020.
- 20 Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. *Jama* 2020.
- 21 Wells PM, Doores KJ, Couvreur S, *et al.* Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. *Journal of Infection* 2020.
- 22 Ward H, Atchison CJ, Whitaker M, *et al.* Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. *medRxiv* 2020:2020.08.12.20173690.
- 23 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, *et al.* Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet* 2020.
- 24 Flower B, Brown JC, Simmons B, *et al.* Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. *Thorax* 2020.



- 25 Wu F, Liu M, Wang A, *et al.* Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. *JAMA internal medicine* 2020;**180**:1356-62.
- 26 Gudbjartsson DF, Norddahl GL, Melsted P, *et al.* Humoral immune response to SARS-CoV-2 in Iceland. *New England Journal of Medicine* 2020.
- 27 Korte W, Buljan M, Rösslein M, *et al.* SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on. *Journal of Infection* 2020.
- 28 Patel MM, Thornburg NJ, Stubblefield WB, *et al.* Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. *JAMA* 2020;**324**:doi:10.1001/jama.2020.18796.
- 29 Muecksch F, Wise H, Batchelor B, *et al.* Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. *medRxiv* 2020:2020.08.05.20169128.
- 30 Kontou PI, Braliou GG, Dimou NL, *et al.* Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. *Diagnostics* 2020;**10**:319.
- 31 Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. *Science Immunology* 2020;**5**:eabd6160.
- 32 Office for National Statistics (ONS), University of Oxford, University of Manchester, *et al.* Coronavirus (COVID-19) Infection Survey pilot: England, Wales and Northern Ireland, 25 September 2020. In: [infection.survey.analysis@ons.gov.uk](mailto:infection.survey.analysis@ons.gov.uk), ed. *Statistical bulletin*: ONS 2020.
- 33 COVID Symptom Study. Day by day evolution of the infection across the UK. In: ZOE Global Limited, Welsh Government, NHS Wales, *et al.*, eds. *COVID: UK Data*: ZOE 2020.

Supplementary Tables

Supplementary Table ST1 Characteristics PGR students

Supplementary Table ST2 Cohort characteristics staff

Supplementary Table ST3 Overall agreement between pairs of COVID-19 outcomes (positive and negative) as a proportion

Supplementary Table ST4 Comparing external antibody testing results with KCL-CHECK antibody test result (in those with external result)

Supplementary Table ST5 Comparing participant reported suspicion of COVID-19 illness (highest suspicion reported April-June) with KCL-CHECK antibody testing result in June

Supplementary Table ST6 Comparing participant reported symptoms (most specific reported April-June) with KCL-CHECK antibody testing result in June

*Supplementary Table ST1 Characteristics PGR students*

		Approximate sampling frame (from KCL Student Office)	Post-Graduate student cohort
Gender	Female	1390 (57%)	229 (73%)
	Male	1070 (43%)	83 (26%)
Age-group	18-24	690 (28%)	50 (16%)
	25-34	1315 (53%)	199 (63%)
	35+	455 (18%)	66 (21%)
Ethnicity group	White	1454 (59%)	248 (79%)
	Mixed	130 (5%)	6 (2%)
	Asian	556 (23%)	37 (12%)
	Black	84 (3%)	6 (2%)
	Other	170 (7%)	16 (5%)
Total		2460	315

*Supplementary Table ST2 Cohort characteristics staff*

		Approximate sampling frame (from KCL Human Resources)	Staff cohort
Gender	Female	5351 (55%)	1110 (71%)
	Male	4368 (45%)	450 (29%)
Age-group	18-24	464 (5%)	40 (3%)
	25-34	3374 (35%)	496 (32%)
	35-44	2755 (28%)	495 (32%)
	45-54	1794 (18%)	276 (18%)
	55-64	1084 (11%)	207 (13%)
	65+	248 (3%)	53 (3%)
Ethnicity group	White	6779 (70%)	1412 (90%)
	Mixed	415 (4%)	23 (1%)
	Asian	1212 (12%)	88 (6%)
	Black	520 (5%)	14 (1%)
	Other	793 (8%)	28 (2%)
Total		9719	1567

*Supplementary Table ST3 Overall agreement between pairs of COVID-19 outcomes (positive and negative) as a proportion*

Complete cohort	Core symptoms	Participant suspicion of COVID	Symptom algorithm	KCL - CHECK antibody test	External testing
Proportion with positive outcome	41%	27%	16%	7%	2%
Agreement:					
Core					
Suspicion	78%				
Algorithm	75%	80%			
KCL -CHECK antibody test	64%	77%	86%		
External test	60%	74%	85%	94%	

Supplementary Table ST4 Comparing external antibody testing results with KCL-CHECK antibody test result (in those with external result)

		External antibody testing				
		Negative	Positive	Total	2x2 stats	
KCL-CHECK antibody test result	Negative	103	14	117	agreement	88%
	Positive	2	19	21 (15%)	(chance agreement)	68%
	Total	105	33 (24%)	138	kappa	0.636
Sensitivity, specificity, PPV and NPV refer to the ability of the KCL-CHECK antibody test to detect those who have tested positive on an external antibody test					sensitivity	58%
					specificity	98%
					Positive predictive value	90%
					Negative predictive value	88%

*Supplementary Table ST5 Comparing participant reported suspicion of COVID-19 illness (highest suspicion reported April-June) with KCL-CHECK antibody testing result in June*

Participant suspicion COVID-19 infection	KCL-CHECK antibody <b>negative</b>	KCL-CHECK antibody <b>positive</b>	%positive	Prevalence ratio, relative to no suspicion
no suspicion (n=597)	593	4	0.7%	ref
unsure (n=776)	757	19	2.4%	3.7
probable COVID (n=401)	342	59	14.7%	22.0
definite COVID (n=108)	66	42	38.9%	58.0
total (n=1882)	1758	124	6.6%	--

*Supplementary Table ST6 Comparing participant reported symptoms (most specific reported April-June) with KCL-CHECK antibody testing result in June*

	KCL-CHECK antibody <b>negative</b>	KCL-CHECK antibody <b>positive</b>	%positive	Prevalence ratio, relative to no symptoms
No symptom (n=642)	632	10	1.6%	ref
Non-core symptom (n=470)	462	8	1.7%	1.1
Core symptom (n=473)	450	23	4.9%	3.1
Symptom algorithm positive (n=297)	214	83	27.9%	17.9
total (n=1882)	1758	124	6.6%	--

Appendix 1:

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Section
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	1
Objectives	3	State specific objectives, including any prespecified hypotheses	1 (descriptive)
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	2.1-2.2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2.1 (and separate protocol)
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	2.1 (and separate protocol)
		(b) For matched studies, give matching criteria and number of exposed and unexposed	n/a
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	2.2
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	2.2
Bias	9	Describe any efforts to address potential sources of bias	n/a
Study size	10	Explain how the study size was arrived at	n/a
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	2.2-2.3
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	2.3
		(b) Describe any methods used to examine subgroups and interactions	n/a
		(c) Explain how missing data were addressed	2.3-3.1
		(d) If applicable, explain how loss to follow-up was addressed	3.1

		(e) Describe any sensitivity analyses	2.3-3.1
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed  (b) Give reasons for non-participation at each stage  (c) Consider use of a flow diagram	Figure 1 / Table 2  Figure 1  Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders  (b) Indicate number of participants with missing data for each variable of interest  (c) Summarise follow-up time (eg, average and total amount)	Table 2-3  Table 2 / 3.1  3.1
Outcome data	15*	Report numbers of outcome events or summary measures over time	Table 3
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included  (b) Report category boundaries when continuous variables were categorized  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	3.2  2.2  n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	3.1
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	4
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	4
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	4
Generalisability	21	Discuss the generalisability (external validity) of the study results	4
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding <sup>a</sup>

Table note (a): KCL-CHECK is funded by King's College London. All investigators are employed by King's College London. Two of the principal investigators are also managers in King's College London. Decisions regarding



study design, analysis, interpretation and decision to publish have been taken by the named investigators without external influence.

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.